Chrome 2001
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
. .
Chrome 2001
Chrome 2001
Health News Health News
New Drug May Boost Survival for Advanced Prostate Cancer Patients: Study
June 02, 2014


MONDAY, June 2, 2014 (HealthDay News) -- A pill that blocks male hormone activity can improve survival and delay the need for chemotherapy in men with advanced prostate cancer, a new clinical trial has found.

Men who took a daily dose of the drug enzalutamide started chemotherapy nearly a year and a half later than men who received a placebo, even though their prostate cancer had spread to other parts of their bodies, said senior study author Dr. Tomasz Beer, deputy director of the Knight Cancer Center at Oregon Health and Science University.

"Generally speaking, you don't want chemotherapy. It's very unpleasant. With enzalutamide, we're able to delay the time to chemotherapy by 17 months, which is very significant for patients," Beer said.

The oral drug also improved survival by nearly a third compared with placebo.

The benefits of enzalutamide were so great that the independent committee overseeing the clinical trial ended it early so the men receiving placebo could be offered the drug, Beer said.

Researchers presented the findings Sunday at the American Society of Clinical Oncology meeting in Chicago. The study was also published simultaneously online in the New England Journal of Medicine.

The trial was funded by pharmaceutical companies Medivation and Astellas Pharma.

Prostate cancer is the second leading cancer killer of men in the United States, behind lung cancer. About one of every seven men will be diagnosed with prostate cancer in their lifetime, and it will kill one in every 36 men, according to the American Cancer Society.

Enzalutamide blocks the ability of male hormones, also called androgens, to bind with prostate cancer cells and fuel their growth.

The drug is already approved by the U.S. Food and Drug Administration for prostate cancer patients who have had chemotherapy, based on its ability to prolong their survival, Beer said. Researchers decided to see if enzalutamide could help men prior to chemotherapy, since it is an easy-to-take pill with fewer side effects than standard chemo.

The trial involved more than 1,700 men located across the globe. Researchers randomly assigned 872 to receive enzalutamide, and the other 845 to take a placebo.

One year into the study, two-thirds of enzalutamide patients showed no progression in their prostate cancer, compared with just 14 percent of patients in the placebo group.

Overall, the pill reduced the risk of death by 29 percent, researchers reported. Seventy-two percent of patients in the enzalutamide group were alive when the trial was halted. In the placebo group, 63 percent were alive at the end of the trial.

Men taking enzalutamide generally began chemotherapy more than two years -- an average of 28 months -- after the start of the clinical trial. The placebo group started chemotherapy around 10.8 months into the trial.

The medication also caused prostate-specific antigen levels to decline by at least half in 78 percent of the men assigned enzalutamide, compared with 3 percent of placebo patients. Doctors use high PSA levels to diagnose prostate cancer.

Side effects included high blood pressure, fatigue, back pain, constipation and joint pain.

"It's an incredibly well-tolerated drug that has some minor side effects," said Dr. Bruce Roth, a professor of oncology at Washington University School of Medicine in St. Louis. "Certainly, anything that can delay the onset of chemotherapy is a plus for patients. There are a number of patients where you're just not ready to pull the trigger on something as toxic as chemotherapy, if you can put it off."

Roth added that enzalutamide appears to work just as well as abiraterone, the only androgen-blocking medication currently approved by the FDA for use in pre-chemo prostate cancer patients. Abiraterone inhibits the body's ability to produce androgen.

"It's at least as good as and possibly has a greater magnitude in reduction of risk of death than abiraterone," Roth said.

Both drugs are expensive, costing $8,000 to $9,000 a month, Roth said.

Roth expects that FDA approval for using enzalutamide prior to chemotherapy could come fairly quickly. "It's a more streamlined process to have the label expanded, compared with a new drug submission," he explained.

More information

Visit the U.S. National Cancer Institute for more on prostate cancer.
Copyright © 2014 HealthDay. All rights reserved.

SOURCES: Tomasz Beer, M.D., F.A.C.P., deputy director, Knight Cancer Center, Oregon Health and Science University, Portland; Bruce Roth, M.D., professor, oncology, Washington University School of Medicine, St. Louis; June 1, 2014, New England Journal ...

More News
InteliHealth .
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
    Print Printer-friendly format    
This website is certified by Health On the Net Foundation. Click to verify.